Brigatinib versus other second-generation ALK inhibitors as initial treatment of anaplastic lymphoma kinase positive non-small cell lung cancer with deep phenotyping: study protocol of the ABP trial

Overview of attention for article published in BMC Cancer, June 2021

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (70th percentile)
High Attention Score compared to outputs of the same age and source (85th percentile)

Mentioned by

twitter: 6 X users

reddit: 1 Redditor

Citations

dimensions_citation: 4 Dimensions

Readers on

mendeley: 17 Mendeley

Summary X Reddit Dimensions citations

So far, Altmetric has seen 8 X posts from 6 X users, with an upper bound of 4,584 followers.

Brigatinib versus other second-generation ALK inhibitors as initial treatment of anaplastic lymphoma kinase positive non-small cell lung cancer with deep phenotyping: study protocol of the ABP trial https://t.co/5rVwieMO7j https://t.co/KdkJ37eM4g

08 Dec 2022

Reply Repost Favourite

Brigatinib versus other second-generation ALK inhibitors as initial treatment of anaplastic lymphoma kinase positive ... https://t.co/GuzRJiMGKg

10 Nov 2021

Reply Repost Favourite

30 Jun 2021

Reply Repost Favourite

PubMed_ Brigatinib versus other second-generation ALK inhibitors as initial treatment of anaplastic lymphoma kinase positive non-small cell lung cancer with deep phenotyping: study protocol of the ABP trial https://t.co/wOglKNkyk3

29 Jun 2021

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 4 additional X posts.